DTU
DTU

Professor Amanda Adler

Picture of AmandaAdler

Position:Director

Telephone:01865 857240

Email:amanda.adler@dtu.ox.ac.uk

Amanda Adler trained in economics, medicine, and epidemiology in the US, and pharmacovigilance in the UK. In 2019, she returned to Oxford University to lead the Diabetes Trial Unit, DTU. The DTU runs studies to address interventions related to diabetes and endocrinology to improve health and collaborates closely with the Health Economic Research Centre.

She chaired a Technology Appraisal Committee at the National Institute for Health and Care Excellence (NICE) for 12 years evaluating over one hundred drugs and devices across disease areas. With NICE, she chaired the committee addressing new models to evaluate and purchase antimicrobials, chaired the Clinical Guidelines for Newer Agents for Type 2 Diabetes and chaired the Quality Standard for Diabetes. She received an award for Distinguished Contribution to NICE at the Parliamentary ceremony celebrating NICE’s 20th anniversary.

She chairs the World Health Organisation Technical Advisory Group for Diabetes. She sees patients who have diabetes in the NHS. She is a Commissioner on the Commission on Human Medicines (CHM) and chairs the CHM’s Expert Advisory Group Cardiovascular, Diabetes, Renal, Respiratory and Allergy, and previously chaired the Medicines and Health Products Regulatory Agency’s Expert Group on the Safety of Insulin. She sits on the National Diabetes Audit Partnership Board and an NIHR funding committee. She supports projects that set priorities under universal health coverage having worked with the UK government, NICE, International Decision Support Initiative, the World Bank, and Organisation for Economic Co-operation and Development (OECD). She is a Fellow of the Royal Statistical Society.

Latest publications

Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment in people with type 2 diabetes in England: a cross-sectional study
Diabetes, obesity & metabolism : 22-Sep-2022 (PubMed)

NICE guidelines on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma
The Lancet. Respiratory medicine : 21-Aug-2022 (PubMed)

How can we optimise health technology assessment and reimbursement decisions to accelerate access to new cardiovascular medicines?
International journal of cardiology : 29-Jul-2022 (PubMed)

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
The lancet. Diabetes & endocrinology : 25-Jul-2022 (PubMed)

Insulin resistance and incident heart failure: a meta-analysis
European journal of heart failure : 03-May-2022 (PubMed)

Glucocorticoid-induced hyperglycaemia and diabetes: Call for action
Diabetic medicine : a journal of the British Diabetic Association : 15-Apr-2022 (PubMed)

Interactions among 17 respiratory pathogens: a cross-sectional study using clinical and community surveillance data
medRxiv : the preprint server for health sciences : 16-Feb-2022 (PubMed)

Nintedanib for treating progressive fibrosing interstitial lung diseases
The Lancet. Respiratory medicine : 21-Nov-2021 (PubMed)

Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study
BMJ open : 28-Sep-2021 (PubMed)

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis
Lancet (London, England) : 30-Aug-2021 (PubMed)

REPRINT OF: CLASSIFICATION OF DIABETES MELLITUS
Diabetes research and clinical practice : 03-Aug-2021 (PubMed)

Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89
Diabetes care : 24-Jun-2021 (PubMed)

Comparison of Symptoms and RNA Levels in Children and Adults With SARS-CoV-2 Infection in the Community Setting
JAMA pediatrics : 11-Jun-2021 (PubMed)

Adjusting for Nonadherence or Stopping Treatments in Randomized Clinical Trials
JAMA : 25-May-2021 (PubMed)

Reply to Are we certain that chlorhexidine gluconate bathing is not beneficial in deducing central line associated blood stream infections among children with cancer or undergoing hematopoietic stem cell transplantation?
Cancer : 04-May-2021 (PubMed)

Viral genomes reveal patterns of the SARS-CoV-2 outbreak in Washington State
Science translational medicine : 04-May-2021 (PubMed)

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis
Lancet (London, England) : 02-May-2021 (PubMed)

Accurate accounting of caplacizumab cost effectiveness - Authors' reply
The Lancet. Haematology : 24-Apr-2021 (PubMed)

The STEP 1 trial for weight loss: a step change in treating obesity?
Nature medicine : 16-Apr-2021 (PubMed)

Effects of weather-related social distancing on city-scale transmission of respiratory viruses: a retrospective cohort study
BMC infectious diseases : 10-Apr-2021 (PubMed)

[Full list of publications]